DE602004020654D1 - Hemmer der mutanten form von kit - Google Patents

Hemmer der mutanten form von kit

Info

Publication number
DE602004020654D1
DE602004020654D1 DE602004020654T DE602004020654T DE602004020654D1 DE 602004020654 D1 DE602004020654 D1 DE 602004020654D1 DE 602004020654 T DE602004020654 T DE 602004020654T DE 602004020654 T DE602004020654 T DE 602004020654T DE 602004020654 D1 DE602004020654 D1 DE 602004020654D1
Authority
DE
Germany
Prior art keywords
kit
hammer
mutant form
mutant
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004020654T
Other languages
English (en)
Inventor
Elisabeth Buchdunger
Doriano Fabbro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE602004020654D1 publication Critical patent/DE602004020654D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance
DE602004020654T 2003-11-18 2004-11-17 Hemmer der mutanten form von kit Active DE602004020654D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52071403P 2003-11-18 2003-11-18
PCT/EP2004/013045 WO2005049032A1 (en) 2003-11-18 2004-11-17 Inhibitors of the mutant form of kit

Publications (1)

Publication Number Publication Date
DE602004020654D1 true DE602004020654D1 (de) 2009-05-28

Family

ID=34619508

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004020654T Active DE602004020654D1 (de) 2003-11-18 2004-11-17 Hemmer der mutanten form von kit

Country Status (28)

Country Link
US (3) US8017621B2 (de)
EP (2) EP1686997B1 (de)
JP (3) JP4762150B2 (de)
KR (1) KR101153647B1 (de)
CN (3) CN102274230B (de)
AT (1) ATE428426T1 (de)
AU (1) AU2004290902B2 (de)
BR (1) BRPI0416680A (de)
CA (1) CA2546189C (de)
CY (1) CY1110354T1 (de)
DE (1) DE602004020654D1 (de)
DK (1) DK1686997T3 (de)
ES (1) ES2324917T3 (de)
HK (1) HK1093680A1 (de)
HR (1) HRP20090390T1 (de)
IL (2) IL175578A (de)
MA (1) MA28176A1 (de)
MX (1) MXPA06005598A (de)
NO (1) NO20062694L (de)
NZ (1) NZ547195A (de)
PL (1) PL1686997T3 (de)
PT (1) PT1686997E (de)
RU (2) RU2405553C1 (de)
SG (1) SG139747A1 (de)
SI (1) SI1686997T1 (de)
TN (1) TNSN06138A1 (de)
WO (1) WO2005049032A1 (de)
ZA (1) ZA200603905B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
AU2004290902B2 (en) 2003-11-18 2008-09-25 Novartis Ag Inhibitors of the mutant form of kit
CA2576926C (en) * 2004-08-31 2012-10-02 Novartis Ag Use of midostaurin for treating gastrointestinal stromal tumors
AU2006242311B2 (en) 2005-05-02 2010-03-04 Novartis Ag Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis
JP5154408B2 (ja) 2005-05-02 2013-02-27 ノバルティス アーゲー 好酸球増加症候群のためのピリミジルアミノベンズアミド誘導体
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
DE602006013826D1 (de) * 2005-07-20 2010-06-02 Peter Valent Zusammensetzungen zur behandlung von systemischer mastocytose
KR101498848B1 (ko) 2005-12-06 2015-03-05 노파르티스 아게 신경섬유종증의 치료를 위한 피리미딜아미노벤즈아미드 유도체
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
EP2073807A1 (de) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmazeutische kombinationen
CN101951910B (zh) * 2008-01-23 2013-07-17 诺瓦提斯公司 优化用伊马替尼治疗酪氨酸激酶受体kit介导的增殖性疾病的制药用途
EP3076966A2 (de) * 2013-12-02 2016-10-12 BerGenBio AS Verwendung von kinasehemmern
CN106188028A (zh) * 2015-05-05 2016-12-07 天津国际生物医药联合研究院 含恶二唑杂环类化合物及其制备方法和应用
WO2018014520A1 (zh) * 2016-07-18 2018-01-25 嘉兴雅康博医学检验所有限公司 用于检测c-kit基因突变的引物、探针及试剂盒
AU2019285066A1 (en) 2018-06-15 2020-12-17 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
US20220010382A1 (en) * 2018-11-12 2022-01-13 Blueprint Medicines Corporation Avapritinib resistance of kit mutants
US20210308133A1 (en) * 2020-04-06 2021-10-07 The Board Of Regents Of The University Of Texas System Methods and compositions for inhibiting muscle wasting

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
TW225528B (de) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
EP0672035A1 (de) 1993-10-01 1995-09-20 Novartis AG Pyrimidinaminderivate und verfahren zu deren herstellung
CZ101496A3 (en) * 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6815791B1 (en) * 1997-02-10 2004-11-09 Fillfactory Buried, fully depletable, high fill factor photodiodes
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB2325934A (en) 1997-06-03 1998-12-09 Polybiomed Ltd Treating metal surfaces to enhance bio-compatibility and/or physical characteristics
WO1998055152A1 (en) 1997-06-06 1998-12-10 Baylor College Of Medicine The mast cell secretory machine as a target for anti-allergy drug development
US5874603A (en) 1997-07-15 1999-02-23 Gelest, Inc. Branched higher alkylsilanes
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CA2309639C (en) 1997-11-13 2010-03-23 John C. Houck Small peptides and methods for treatment of asthma and inflammation
US20040157855A1 (en) * 2001-04-05 2004-08-12 Michael Heinrich Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
EP1401429A2 (de) 2001-06-29 2004-03-31 AB Science Die verwendung von potenten, selektiven und nontoxischen c-kithemmer zur behandlung von mastocysosis
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20050095237A1 (en) 2001-12-11 2005-05-05 Emtage Peter C. Methods of therapy and diagnosis using targeting of cells that express P2Y10
US20050118600A1 (en) * 2002-03-13 2005-06-02 Yuko Aoki Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20080096864A1 (en) * 2003-09-19 2008-04-24 Sasa Dimitrijevic Treatment Of Gastrointestinal Stromal Tumors With Imatinib And Midostaurin
AU2004290902B2 (en) 2003-11-18 2008-09-25 Novartis Ag Inhibitors of the mutant form of kit
AU2006242311B2 (en) 2005-05-02 2010-03-04 Novartis Ag Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis
CN200998572Y (zh) * 2007-01-29 2008-01-02 深圳市龙岗区坪山宽富高尔夫器具厂 可携带配件的高尔夫球杆头套
JP5448036B2 (ja) * 2009-02-18 2014-03-19 トヨタ自動車株式会社 カルボン酸の製造方法

Also Published As

Publication number Publication date
AU2004290902A1 (en) 2005-06-02
SG139747A1 (en) 2008-02-29
NO20062694L (no) 2006-06-12
RU2009110449A (ru) 2010-09-27
US20100179179A1 (en) 2010-07-15
CN101693031A (zh) 2010-04-14
TNSN06138A1 (fr) 2007-11-15
SI1686997T1 (sl) 2009-08-31
CN102274230A (zh) 2011-12-14
EP1686997B1 (de) 2009-04-15
US20120157441A1 (en) 2012-06-21
CN102274230B (zh) 2015-07-01
PT1686997E (pt) 2009-07-17
RU2006121447A (ru) 2008-01-10
CY1110354T1 (el) 2015-04-29
ES2324917T3 (es) 2009-08-19
US8017621B2 (en) 2011-09-13
MXPA06005598A (es) 2006-08-11
CA2546189C (en) 2013-04-23
WO2005049032A1 (en) 2005-06-02
MA28176A1 (fr) 2006-09-01
RU2405553C1 (ru) 2010-12-10
KR20060101761A (ko) 2006-09-26
PL1686997T3 (pl) 2009-09-30
NZ547195A (en) 2010-06-25
ATE428426T1 (de) 2009-05-15
US20070213317A1 (en) 2007-09-13
US8124611B2 (en) 2012-02-28
EP1686997A1 (de) 2006-08-09
CN1882344A (zh) 2006-12-20
JP2011121973A (ja) 2011-06-23
DK1686997T3 (da) 2009-07-27
JP2007511567A (ja) 2007-05-10
IL175578A (en) 2013-10-31
AU2004290902B2 (en) 2008-09-25
ZA200603905B (en) 2008-11-26
HK1093680A1 (en) 2007-03-09
JP4762150B2 (ja) 2011-08-31
HRP20090390T1 (hr) 2009-08-31
BRPI0416680A (pt) 2007-02-13
IL229124A0 (en) 2013-12-31
KR101153647B1 (ko) 2012-06-18
JP2013241438A (ja) 2013-12-05
RU2362562C2 (ru) 2009-07-27
EP1917965A1 (de) 2008-05-07
IL175578A0 (en) 2008-04-13
CA2546189A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
NO20062694L (no) Inhibitor av mutant form av KIT
ATE510534T1 (de) Naltrexonhydrochlorid-zusammensetzungen
BR0310092A (pt) Combinação de compostos orgânicos
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
DK1583541T3 (da) Forbindelser og fremgangsmåder til at øge neurogenese
BR0213981A (pt) Fotoiniciadores difuncionais
ATE368034T1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
EA200400971A1 (ru) Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
IS7337A (is) Nikótínamíð afleiður nytsamlegar sem P38 hindrar
DE60223923D1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
DK1392282T3 (da) Dermatologiske og kosmetiske sammensætninger, der omfatter et furfurylderivat
NO20065117L (no) Sammensetning omfattende en JNK inhibitor og syklosporin.
NO20051521L (no) Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt
NO20052839L (no) NADH/NADPH-inneholdende sammensetning
EA200501584A1 (ru) Бета-карболины, применяемые для лечения воспалительных заболеваний
DE50101827D1 (de) Neue derivate und analoga von galanthamin
ATE469886T1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
CY1107039T1 (el) Αναστολεις τριπεπτιδυλ πεπτιδασης
DE602005010369D1 (de) 2-thiaquinolizidines als Glycosidase- und Glycosyltransferase-Inhibitoren
ATE527280T1 (de) Fluoreszentprotein und chromoprotein
DK1644385T3 (da) Siliciumforbindelser og deres anvendelse
DE602004004776D1 (de) Benzothiazole derivate und ihre anwendung in der behandlung von adenosine a2a rezeptor vermittelte krankheiten
ATE360415T1 (de) Behandlung von dyskinesie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN